Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase

S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri, Christopher W. Ryan, Margaret Von Mehren, Robert S. Benjamin, A. Kevin Raymond, Vivien H C Bramwell, Laurence H. Baker, Robert G. Maki, Michael Tanaka, J. Randolph Hecht, Michael C. Heinrich, Christopher D M Fletcher, John J. Crowley, Ernest C. Borden

Research output: Contribution to journalArticle

711 Citations (Scopus)

Abstract

Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. Results: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.

Original languageEnglish (US)
Pages (from-to)626-632
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number4
DOIs
StatePublished - Feb 1 2008

Fingerprint

Gastrointestinal Stromal Tumors
Receptor Protein-Tyrosine Kinases
Disease-Free Survival
Survival
Imatinib Mesylate
Canada
Disease Progression
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase : S0033. / Blanke, Charles D.; Rankin, Cathryn; Demetri, George D.; Ryan, Christopher W.; Von Mehren, Margaret; Benjamin, Robert S.; Raymond, A. Kevin; Bramwell, Vivien H C; Baker, Laurence H.; Maki, Robert G.; Tanaka, Michael; Randolph Hecht, J.; Heinrich, Michael C.; Fletcher, Christopher D M; Crowley, John J.; Borden, Ernest C.

In: Journal of Clinical Oncology, Vol. 26, No. 4, 01.02.2008, p. 626-632.

Research output: Contribution to journalArticle

Blanke, CD, Rankin, C, Demetri, GD, Ryan, CW, Von Mehren, M, Benjamin, RS, Raymond, AK, Bramwell, VHC, Baker, LH, Maki, RG, Tanaka, M, Randolph Hecht, J, Heinrich, MC, Fletcher, CDM, Crowley, JJ & Borden, EC 2008, 'Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033', Journal of Clinical Oncology, vol. 26, no. 4, pp. 626-632. https://doi.org/10.1200/JCO.2007.13.4452
Blanke, Charles D. ; Rankin, Cathryn ; Demetri, George D. ; Ryan, Christopher W. ; Von Mehren, Margaret ; Benjamin, Robert S. ; Raymond, A. Kevin ; Bramwell, Vivien H C ; Baker, Laurence H. ; Maki, Robert G. ; Tanaka, Michael ; Randolph Hecht, J. ; Heinrich, Michael C. ; Fletcher, Christopher D M ; Crowley, John J. ; Borden, Ernest C. / Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase : S0033. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 4. pp. 626-632.
@article{9f8212d450c64a20be5810c3e6bc2bde,
title = "Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033",
abstract = "Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. Results: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33{\%} of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.",
author = "Blanke, {Charles D.} and Cathryn Rankin and Demetri, {George D.} and Ryan, {Christopher W.} and {Von Mehren}, Margaret and Benjamin, {Robert S.} and Raymond, {A. Kevin} and Bramwell, {Vivien H C} and Baker, {Laurence H.} and Maki, {Robert G.} and Michael Tanaka and {Randolph Hecht}, J. and Heinrich, {Michael C.} and Fletcher, {Christopher D M} and Crowley, {John J.} and Borden, {Ernest C.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1200/JCO.2007.13.4452",
language = "English (US)",
volume = "26",
pages = "626--632",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase

T2 - S0033

AU - Blanke, Charles D.

AU - Rankin, Cathryn

AU - Demetri, George D.

AU - Ryan, Christopher W.

AU - Von Mehren, Margaret

AU - Benjamin, Robert S.

AU - Raymond, A. Kevin

AU - Bramwell, Vivien H C

AU - Baker, Laurence H.

AU - Maki, Robert G.

AU - Tanaka, Michael

AU - Randolph Hecht, J.

AU - Heinrich, Michael C.

AU - Fletcher, Christopher D M

AU - Crowley, John J.

AU - Borden, Ernest C.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. Results: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.

AB - Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. Results: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.

UR - http://www.scopus.com/inward/record.url?scp=39149127634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149127634&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.13.4452

DO - 10.1200/JCO.2007.13.4452

M3 - Article

VL - 26

SP - 626

EP - 632

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -